Pacer Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $410M | Sell |
2,945,242
-436,567
| -13% | -$61.1M | 1.15% | 7 |
|
|
2025
Q4 | $415M | Sell |
3,381,809
-208,936
| -6% | -$25.4M | 1.06% | 15 |
|
|
2025
Q3 | $399M | Sell |
3,590,745
-528,977
| -13% | -$60.1M | 1% | 24 |
|
|
2025
Q2 | $457M | Sell |
4,119,722
-765,414
| -16% | -$81.5M | 1.14% | 17 |
|
|
2025
Q1 | $547M | Sell |
4,885,136
-1,549,529
| -24% | -$160M | 1.28% | 7 |
|
|
2024
Q4 | $594M | Buy |
6,434,665
+5,653,075
| +723% | +$509M | 1.28% | 1 |
|
|
2024
Q3 | $65.5M | Sell |
781,590
-7,108,073
| -90% | -$542M | 0.14% | 177 |
|
|
2024
Q2 | $541M | Buy |
7,889,663
+1,564,792
| +25% | +$104M | 1.23% | 1 |
|
|
2024
Q1 | $463M | Buy |
6,324,871
+1,278,219
| +25% | +$98.3M | 1.07% | 14 |
|
|
2023
Q4 | $409M | Buy |
5,046,652
+493,920
| +11% | +$38.4M | 1.16% | 9 |
|
|
2023
Q3 | $341M | Buy |
4,552,732
+831,107
| +22% | +$63.9M | 1.31% | 8 |
|
|
2023
Q2 | $287M | Buy |
3,721,625
+228,183
| +7% | +$18.2M | 1.15% | 10 |
|
|
2023
Q1 | $290M | Buy |
3,493,442
+867,597
| +33% | +$71.9M | 1.24% | 6 |
|
|
2022
Q4 | $225M | Sell |
2,625,845
-15,231
| -0.6% | -$1.21M | 1.15% | 5 |
|
|
2022
Q3 | $163M | Buy |
2,641,076
+114,944
| +5% | +$7.25M | 1.14% | 5 |
|
|
2022
Q2 | $156M | Buy |
2,526,132
+1,195,509
| +90% | +$74M | 1.16% | 7 |
|
|
2022
Q1 | $79.1M | Buy |
1,330,623
+836,884
| +169% | +$53.5M | 0.65% | 31 |
|
|
2021
Q4 | $35.9M | Buy |
493,739
+74,236
| +18% | +$5.11M | 0.37% | 34 |
|
|
2021
Q3 | $29.3M | Buy |
419,503
+52,013
| +14% | +$3.65M | 0.37% | 30 |
|
|
2021
Q2 | $25.3M | Buy |
367,490
+116,320
| +46% | +$7.77M | 0.36% | 31 |
|
|
2021
Q1 | $16.2M | Buy |
251,170
+2,316
| +0.9% | +$149K | 0.28% | 49 |
|
|
2020
Q4 | $14.5M | Sell |
248,854
-6,193
| -2% | -$374K | 0.27% | 54 |
|
|
2020
Q3 | $16.1M | Sell |
255,047
-14,661
| -5% | -$1.02M | 0.34% | 46 |
|
|
2020
Q2 | $20.8M | Buy |
269,708
+62,776
| +30% | +$4.81M | 0.42% | 46 |
|
|
2020
Q1 | $17.4M | Buy |
206,932
+107,270
| +108% | +$7.41M | 0.35% | 23 |
|
|
2019
Q4 | $6.48M | Sell |
99,662
-199,684
| -67% | -$13M | 0.29% | 54 |
|
|
2019
Q3 | $19M | Buy |
299,346
+18,031
| +6% | +$1.18M | 0.43% | 43 |
|
|
2019
Q2 | $19M | Buy |
281,315
+20,767
| +8% | +$1.37M | 0.46% | 37 |
|
|
2019
Q1 | $16.9M | Buy |
260,548
+210,220
| +418% | +$14M | 0.47% | 41 |
|
|
2018
Q4 | $3.15M | Sell |
50,328
-169,864
| -77% | -$11.9M | 0.11% | 36 |
|
|
2018
Q3 | $17M | Buy |
220,192
+53,165
| +32% | +$4.02M | 0.64% | 17 |
|
|
2018
Q2 | $11.8M | Buy |
167,027
+30,447
| +22% | +$2.15M | 0.54% | 19 |
|
|
2018
Q1 | $10.3M | Buy |
136,580
+28,476
| +26% | +$2.26M | 0.57% | 22 |
|
|
2017
Q4 | $7.75M | Buy |
108,104
+23,402
| +28% | +$1.78M | 0.54% | 19 |
|
|
2017
Q3 | $6.86M | Buy |
84,702
+7,617
| +10% | +$582K | 0.61% | 17 |
|
|
2017
Q2 | $5.46M | Buy |
77,085
+31,724
| +70% | +$2.11M | 0.54% | 20 |
|
|
2017
Q1 | $3.08M | Buy |
45,361
+4,651
| +11% | +$327K | 0.38% | 37 |
|
|
2016
Q4 | $2.92M | Buy |
40,710
+779
| +2% | +$57.9K | 0.42% | 33 |
|
|
2016
Q3 | $3.16M | Sell |
39,931
-2,996
| -7% | -$243K | 0.48% | 30 |
|
|
2016
Q2 | $3.58M | Buy |
42,927
+955
| +2% | +$84.8K | 0.57% | 22 |
|
|
2016
Q1 | $3.86M | Buy |
41,972
+813
| +2% | +$73.3K | 0.88% | 18 |
|
|
2015
Q4 | $4.17M | Buy |
+41,159
| New | +$4.28M | 0.98% | 15 |
|
|
2013
Q4 | $407K | Buy |
+4,315
| New | +$300K | 0.1% | 269 |
|
Other funds holding GILD
VCM
VPM
Pacer Advisors's GILD Position: Q1 2026 in Review
Pacer Advisors reduced its Gilead Sciences (GILD) stake by 13% in Q1 2026, selling an estimated $61.1M and leaving 2,945,242 shares worth $410M. The position accounts for 1.15% of the portfolio, ranked #7.
Pacer Advisors first reported a position in GILD in Q4 2013 and has held it in 43 quarters since. The position peaked at $594M in Q4 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Pacer Advisors held 2,945,242 shares of Gilead Sciences worth $410M as of Q1 2026.
- Pacer Advisors sold 436,567 Gilead Sciences shares in Q1 2026, an estimated $61.1M.
- Gilead Sciences made up 1.15% of Pacer Advisors's portfolio in Q1 2026, its #7 holding.
- Pacer Advisors first reported a position in Gilead Sciences in Q4 2013 and has held it in 43 quarters since.
- Pacer Advisors's Gilead Sciences position peaked at $594M in Q4 2024.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.